SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Sanofi Consumer Healthcare India Ltd

BSE: 544250 NSE: SANOFICONR ISIN: INE0UOS01011
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Sanofi Consumer Healthcare India Ltd belong to?
Sanofi Consumer Healthcare India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Sanofi Consumer Healthcare India Ltd a good quality company?
Sanofi Consumer Healthcare India Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Sanofi Consumer Healthcare India Ltd undervalued or overvalued?
Sanofi Consumer Healthcare India Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Sanofi Consumer Healthcare India Ltd a good buy now?
Sanofi Consumer Healthcare India Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd revenue growth is 30.5% for FY-2024 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Gross profit margin which is the profit after deduction of direct costs, is 37% for FY-2024 , which is above its 5 year median of 18.5% , indicating increasing margins.
Q.3 Operating Profit Margin of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 37.35% for FY-2024 , which is above its 5 year median of 18.68% indicating increasing margins.
Q.4 Net Profit Margin of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Net Profit Margin is 24.98% for FY-2024 , is above with its 5 year median of 12.49%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 37 18.5
Operating Profit Margin 37.35 18.68
Net Profit Margin 24.98 12.49
Q.5 Return on Asset of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Return on Asset is 40.67%, which is above its 5 year historical median of 20.34%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Return on equity is 79.28% for FY-2024 , which is above its historical median of 39.64%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Return on capital employed is 104.33% for FY-2024 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Cash conversion cycle is -18 days, below its historical median of -9 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.7 0.84
ROE 79.28 39.64
ROCE 104.33 52.17
Cash Conversion Cycle -18 days -9 days
Q.9 Debt to Equity ratio of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Sanofi Consumer Healthcare India Ltd?
Promoters hold 71.27% of the Sanofi Consumer Healthcare India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Sanofi Consumer Healthcare India Ltd vs industry peers?
Sanofi Consumer Healthcare India Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 724.5 137.1
Gross Profit 268.3 15.1
Operating Profit 271 16
Net Profit 181 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.7 0.8
ROE 79.28 8.91
ROCE 104.33 11.59
Cash Conversion Cycle (days) -18.23 76

Valuation & price assessment

Q.1 Stock return of Sanofi Consumer Healthcare India Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -4.34% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -4.3%
Q.3 Valuation ratios of Sanofi Consumer Healthcare India Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 45.29 54.99 40.28
Price to Book 28.32 0.00 2.77
Price to Sales 12.38 15.19 2.65
EV to EBITDA 32.07 38.58 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×